| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Randomized Controlled Trial |
| Article Title |
Tenofovir disoproxil fumarate in Chinese chronic hepatitis B patients: Results of a multicenter, double-blind, double-dummy, clinical trial at 96-week
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xiao-Fan Chen, Ya-Nan Fan, Chong-Wen Si, Yan-Yan Yu, Jia Shang, Zu-Jiang Yu, Qing Mao, Qing Xie, Wei Zhao, Jun Li, Zhi-Liang Gao, Shan-Ming Wu, Hong Tang, Jun Cheng, Xin-Yue Chen, Wen-Hong Zhang, Hao Wang, Zhong-Nan Xu, Ling Wang, Jun Dai and Jing-Hang Xu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| The 13th Five-year Science and Technology Major Project of China, on the Prevention and Treatment of Major Infectious Diseases |
2017ZX10202202 |
|
| Corresponding Author |
Jing-Hang Xu, MD, PhD, Professor, Department of Infectious Diseases, Center for Liver Diseases, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China. ddcatjh@sina.com |
| Key Words |
Chronic hepatitis B; Hepatitis B virus infection; Chronic; Tenofovir disoproxil fumarate; Randomized-controlled trial; Treatment outcomes; Noninferiority trial |
| Core Tip |
This clinical trial compared the efficacy and safety of Qingzhong and Viread, two commercialized tenofovir disoproxil fumarate drugs, in the treatment of Chinese chronic hepatitis B (CHB) patients during a 96-wk period. The decrease in mean hepatitis B virus DNA level relative to the baseline value, the rates of hepatitis B e antigen (HBeAg) loss and HBeAg seroconversion, and the incidence of adverse events were all comparable between patients treated with the two drugs. Our results indicate that both Qingzhong and Viread were effective and safe in the treatment of Chinese CHB patients. |
| Publish Date |
2021-06-11 09:22 |
| Citation |
Chen XF, Fan YN, Si CW, Yu YY, Shang J, Yu ZJ, Mao Q, Xie Q, Zhao W, Li J, Gao ZL, Wu SM, Tang H, Cheng J, Chen XY, Zhang WH, Wang H, Xu ZN, Wang L, Dai J, Xu JH. Tenofovir disoproxil fumarate in Chinese chronic hepatitis B patients: Results of a multicenter, double-blind, double-dummy, clinical trial at 96-week. World J Clin Cases 2021; 9(18): 4690-4699 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i18/4690.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i18.4690 |
